July 1, 2019
A Q&A with Keith Flaherty, MD, Associate Professor of Medicine, Harvard Medical School; Director of Developmental Therapeutics, Cancer Center, Massachusetts General Hospital; email@example.com Originally published Aug 31, 2016 Q: Under what circumstances and to what extent are you willing to take clinical actions on a cancer patient based primarily on preclinical data? A: There are two scenarios that come to mind when thinking about… Read more »
August 11, 2017
New Online Navigator Helps Patients and Doctors Access Experimental TreatmentsBookmarkEmma Shtivelman, PhD
“When approved therapies don’t work, or stop working, for people with serious or life-threatening illnesses, it puts them in a difficult position. Some turn to clinical trials that are testing experimental treatments. But many can’t do that because they are too sick, don’t meet the requirements of the trial, or can’t afford to travel to the site of a trial. That doesn’t mean they are out of options.”
If you’re wondering whether this story applies to your own cancer case or a loved one’s, we invite you to get support from Cancer Commons.